

REMARKS

The Notice indicates that the Applicants amended claims 86, 87 and 93 to include sequences, however, the application does not have any biotechnological data present and therefore has not met the requirements as set forth in 37 C.F.R. §§ 1.821-1.825.

In response to the Notice, Applicants submit herewith a Sequence Listing in order to comply with the Sequence Listing Requirements of 37 C.F.R. §§ 1.821-1.825. Applicants respectfully request entry of the attached sequence listing (electronic copy) into the application and be incorporated by reference in its entirety. Applicants respectfully submit that no new matter has been entered by these submissions.

AUTHORIZATION


No fee is believed due. However, the Commissioner is hereby authorized to charge is hereby authorized to charge any additional fees, or credit any overpayment, to Deposit Account No. 50-3732, order no. 13720-105071.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 50-3732, Order No. 13720-105071.

Respectfully submitted,
King & Spalding, LLP

Dated: April 4, 2011

By: _____


Joseph D. Eng, Jr.
Reg. No. 54,084

Correspondence Address:
Customer Number 65989
King & Spalding
1185 Avenue of the Americas
New York, NY 10036-4003
(212) 556-2100 Telephone
(212) 556-2222 Facsimile